Farminpex’s Post

The article "Research Integrity in Guidelines and evIDence synthesis (RIGID)" by Aya Mousa et al. introduces the RIGID framework, developed to address the lack of processes for incorporating integrity assessments in evidence-based guideline development. This framework consists of six steps: review, exclude, assess, discuss, establish contact, and reassess. It ensures that only reliable and trustworthy studies inform clinical guidelines, thus protecting patient care and maintaining scientific credibility. https://lnkd.in/gJfZwN2C #ResearchIntegrity #EvidenceBasedMedicine #ClinicalGuidelines

Today, kicks off our 4th annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, hosted by #LupusTherapeutics, the clinical affiliate of the Lupus Research Alliance. This annual meeting brings people with #lupus together with thought leaders, clinical investigators, study coordinators, research & industry partners to discuss the progress and advancements being made in #LupusClinicalResearch and treatment, and the importance of health equity and access in #lupus clinical trials. Learn more about LuCIN at https://bit.ly/LuCIN2024 #LuCINCommunity #LupusAwarenessMonth

Major advances in paediatric eczema care! 🌟 The past decade has brought remarkable insights into atopic dermatitis, unveiling new therapies that offer transformative results with lasting impact. 🔗 Discover more in our Scientific Blog at eadv.org/scientific/blog #EADV #AtopicDermatitis

NEW DEADLINE: submission of abstracts for the 3rd OPMDay has been extended until April 14th: https://lnkd.in/d2-jrv_n The OPMDay is a two-day conference focusing on #oralpotentiallymalignantdisorders (OPMDs) and the flagship event of INTERCEPTOR, a project financed by the COST Association - European Cooperation in Science and Technology. Abstracts must fall under one of the following categories: “original studies”, “work-in-progress”, “new trial ideas/concepts”, and “study proposals seeking new collaborations”. Submissions by #youngresearchers and #students is strongly encouraged. The goal is to foster networking and collaboration among experts in the field of #oralcancer #prevention and to develop a new multidisciplinary approach that may help to reorganize disease care management, while fostering support for #patients affected by OPMD and enhancing the #prevention of #malignant transformation of these lesions. This year's meeting will be hosted at the Faculdade de Medicina da Universidade do Porto. Save the date: https://lnkd.in/d95G-Gch

The demand •worldwide• for MAPS-trained practitioners has never been greater than it is right NOW! If you are an international practitioner, please join us virtually this September 5-7th for our Fall CME Functional and Translational Medicine Conference. Email KMorris@MedMaps.org for your personal virtual registration link! #Virtual #MAPS #Global #infancytoadulthood #CME #functionalmedicine #fall2024 #2024AAP #specialneeds #medicine

For patients and non-specialists, understanding AFib and its treatments can be complex. StoryMine's video for the New England Journal of Medicine (NEJM Group) aims to break down AFib clearly and efficiently, showcasing advancements in medical knowledge. We sought clear explanations of AFib diagnosis and treatment, highlighting the evolution of medical understanding from past uncertainties to current treatments. Utilizing historical context as a storytelling tool, we engaged viewers by illustrating progress and discovery in the field. We created two versions of the video: one tailored for patients and families, showcasing the journey of medical advancement in AFib management, including insights on anti-arrhythmic medications and catheter ablation procedures. The second video was designed for a primary care audience, incorporating more instructional elements. #Healthcare #AFib #medicalvideostories https://lnkd.in/exYgj8FC

The Journal of Clinical and Translational Science (JCTS) has just published a new thematic issue: COVID-19 Therapeutic Platform Trials Lessons Learned. In this issue, the ACTIV Therapeutics-Clinical Working Groups (WGs) and Clinical Trial Teams document valuable lessons believed to benefit future healthcare leaders and researchers faced with preparing for and responding to global public health emergencies. Read these select manuscripts and more today! https://buff.ly/3Yxn4KU

Strategies to provide your patients with prurigo nodularis (PN) and atopic dermatitis (AD) much needed relief! Join us LIVE at Fall Clinical for expert insights on the etiology of itch and pearls from Dr. Shawn Kwatra, Dr. Tejesh Patel, and Dr. Mona Shahriari, as they discuss the application of new and emerging treatments in clinical practice! Check more of the #fallclinical agenda below: https://lnkd.in/eh7zrFTM

💫 We are delighted to announce the recent publication of the paper titled "Potential Drug-Drug Interactions in Hospitalized Patients," authored by Prof. Afrim Tabaku (Chief Member of GREEN, IAS, and AIREC) and collaborators. This important study has been published in the International Journal of Biomed Insights (IJBMI). The research provides an in-depth analysis of potential drug-drug interactions (DDIs) among hospitalized patients, identifying key factors that contribute to interaction risks and their clinical implications. By examining a diverse patient population, the study offers valuable insights into the frequency, severity, and types of interactions that can occur within a hospital setting. These findings are essential for healthcare professionals aiming to enhance patient safety, optimize therapeutic outcomes, and minimize adverse effects linked to polypharmacy. To access the full paper, please follow the link below: https://lnkd.in/e5Y_YqMb GREEN

Kudos to National Center for Advancing Translational Sciences (NCATS) for organizing an exciting #rarediseaseday2024 that featured many inspiring stories from patients, researchers, and clinicians. Our founder, Dr. Anne Chiaramello, Deputy Clinical Director Dr. Andrea Gropman and Deputy Scientific Director Dr. Martine Uittenbogaard attended; and all three walked away with real information that will be useful in NCATS funded clinical trial for two rare mitochondrial diseases. We will be sharing more insights soon, including a fascinating pictorial of the convoluted, and often frustrating, rare disease patient journey, presented by Dr. Kimberly Moran, PhD, MBA. Dr. Dominique Pichard's talk on #NCATS mission encapsulated the progress thus far accomplished for rare diseases by creating a seamless interface among patient advocacy groups, researchers, and clinicians to improve diagnosis and augmenting the number of treatments in the #drugdevelopment. What an inspirational day at The National Institutes of Health! Many thanks to Dr. Joni L Rutter, Director of #NCATS, and Dr. Monica Bertagnolli, #NIH Director, for shining the light on patients living with a #raredisease and their commitment to find a cure for #rarediseases. #rarediseaseawareness #mitochondrialdisease #lhonplus #melas #clinicaltrials #personalizedmedicine